Pharmafile Logo

The Clinical Trial Company

The Clinical Trial Company (TCTC) targets medium size clinical trials and novel products which lack a classical road map to the market.
Large CROs prioritise studies from the big pharma companies, for good business reasons. However, this approach sometimes disadvantages their SME clients who are equally keen to complete their clinical trials quickly. TCTC are experts in advanced therapies, such as cell and gene therapies, as well as orphan drug and biologics.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Havas Life London

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…

View Profile

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…

View Profile

Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.

View Profile

Uniphar

Uniphar Group is a trusted global partner to pharmaceutical, medtech, and supply chain and retail companies, working to improve patient access to medicines around the world.

View Profile

Company Details

Mere View Barn, Park Lane, Pickmere, Knutsford, WA16 0LG, UK
+44 1565 733 772

 Latest Content from PMHub 

News: Research Partnership is listed in the Alantra Pharma Fast 50 annual report

The best performing privately-owned UK pharmaceutical businesses were revealed earlier this month with the publication of Pharma Times’ Alantra Pharma Fast 50 annual report.Read more about this report here

Event: Blending data science and market research at the Data Analytics & Insight conference

Last month Analytics Director Misti Paul attended the Data Analytics & Insight Conference. In our latest blog post she reflects on the presentations that were given and what lessons can be...

Presentation: Optimize your digital assets with UX research

US Director Liza Pliss recently presented the paper 'Optimize your digital assets with UX research' at the PMR Conference in New Jersey, USA. Don't worry if you missed it though,...

Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase

We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada. The reports consist of 30-minute quantitative online and qualitative telephone interviews with RA patients. Read more on...

Infographic: Rheumatoid arthritis (RA)

An overview of the RA biologic patientOur RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at...

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only...

Rewarding excellence within Porterhouse Medical’s scientific services team.

At Porterhouse Medical, we are very proud of our hard-working teams and are always delighted to recognise career progression within the agency. With this in mind, we are thrilled to...

How to go BIG with your pharma exhibition stand design

At Apex, we believe that you don’t need to go for a huge exhibition stand if you want to get noticed. In fact, with a talented exhibition stand design team...

Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

Authors: Keir LoIacono, John Rodriguez, Daniel J. O’Connor, James R. Nitzkorski, MD*, Christopher G. Twitty, PhDAffiliations: OncoSec Medical Incorporated, San Diego, CA, and Pennington, NJ, *Division of Surgical Oncology, Vassar...